All News

Full traditional approval follows accelerated approval of the medication last year.

The evolving treatment landscape for multiple myeloma includes debates on the timing and effectiveness of CAR T-cell therapy and quadruple immunotherapy regimens.

Edaravone and dexborneol sublingual tablets are an innovative first drug to be designed for treatment of stroke and granted this designation.

RSV vaccination was 75% effective in preventing RSV-associated hospitalizations among adults aged 60 years and older.

Reid Merryman, MD, discusses the potential for minimal residual disease (MRD) to inform treatment decisions, identify lymphoma subgroups, and infer gene expression.

Disease-related factors include several prognostic scoring systems, such as DIPSS, whereas patient-related factors involve age, comorbidities, spleen size, and anemia.

New transparency initiatives will go into effect on January 1, 2025, building off previous actions by the Centers of Medicare and Medicaid Services.

A pharmacist with Allegheny Health Network discusses travel vaccines and what resources are valuable when determining which vaccinations are needed prior to travel.

ALZ-801 has now progressed to the phase 3 APOLLOE4 study, designed to evaluate efficacy, safety, and biomarker and imaging effects.

Surprisingly, those with overweight BMI at diagnosis did not have a poor prognosis.

Optimizing outcomes for patients with chronic myeloid leukemia (CML) requires personalized treatment, adaptive dosing, and precise genetic insights.

Stefan Barta, MD, MS, MRCPCUK, discusses the potential role of biomarkers in predicting treatment outcomes, the emerging use of CAR T-cell therapy, and the benefits and challenges of combination therapies in managing T-cell lymphoma.

Previously, the FDA granted fast track designation to ABD-147 (Abdera Therapeutics Inc) for extensive stage small cell lung cancer.

Sonali Smith, MD, discusses T-cell–directed therapies for indolent B-cell lymphoma, focusing on their efficacy, FDA-approved treatments, and treatment challenges, such as managing cytokine release syndrome.

Rather than “trial-and-erroring” transplants for patients, experts should instead select transplants that are precise, personalized, and predictable.

The risk of therapy duplication with OTC and prescription PPIs can be lowered with an innovative, multi-faceted, and intentional approach by pharmacy teams and prescribers.

There is no significant impact on maternal or infant health outcomes when taking an additional iron supplement

Intravenous immunoglobulin (IVIG) therapy was found to have statistically significant positive effects on live birth rates, implantation rate, and other indicators.

The Center for Innovation & Value Research has released a final report recommending strategies to ensure health equity is integrated into health technology assessment, which can influence drug pricing and selection by payers, as well as patient access to drugs.

Lauren Posteraro, PharmD, a pharmacist with AHN, discusses how misinformation and access to technology can contribute to vaccine hesitancy.

Educators describe a project where they used TikTok to encourage students to develop innovative informatics and medication safety technologies for fun, engaging learning.

New insights into heart failure risks in Native American communities are highlighting the need to address social determinants of health.

OBX-115 could offer further treatment options for individuals with advanced or metastatic melanoma by enhancing persistence, antitumor activity, and clinical safety of TIL cell therapy.

The authors stress that health care providers should explain false positive results to their patients, reassure them that results may be negative, and stress the significance of continued screenings.

Alirocumab (Praluent; Regeneron), is a PCSK9 inhibitor indicated for the treatment of adults with heterozygous familiar hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease.

These companion diagnostics are poised to provide simpler and detailed insights into a patient’s genomic alternations, which could improve outcomes for patients with prostate cancer.

In a promising development in multiple sclerosis research, tolebrutinib delayed the onset of disability progression in patients with nrSPMS.

Pharmacists can enhance ASCVD management by supporting patient adherence through the administration and monitoring of inclisiran.